BioSpace News Archive

Senhwa Biosciences, Inc. (TPEx: 6492), today announced its clinical partner- Center for Advanced Research and Education (CARE) in Gainesville, Georgia, has received a Study May Proceed letter from the US Food and Drug Administration (FDA) to begin a phase II investigator-initiated trial (IIT) evaluating Silmitasertib,

-OrthAlign, Inc., a privately held U.S.-based medical device and technology company providing orthopedic surgeons with advanced precision technologies, announced the first cases using LANTERN™ Surgical Assistant

OncoMyx Therapeutics, a privately held oncolytic immunotherapy company, today announced the appointment of Charles (Chuck) M. Baum, M.D., Ph.D., as chairperson of the company’s board of directors.

Mispro Biotech Services, a contract vivarium company with a network of locations in the U.S. and Canada, has recently opened the doors to a brand-new vivarium research facility located off of Gateway Blvd. in the heart of South San Francisco’s life sciences corridor.

Novālent Biotech, Inc (‘Novālent’), a US biotechnology engineering firm, promotes Mike Motta from vice president to Chief Commercial Officer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201106005325/en/ Mike Motta, Chief Commercial Officer at Novālent, a US biotechnology engineering firm having an extensive set of ‘industry first’ EPA registration

Company Being Sought Out Worldwide for Global Distribution Agreements Based Testing at FDA; CLIA Certified Lab

MYOS RENS Technology Inc. (“MYOS” or the “Company”) (NASDAQ: MYOS), an advanced nutrition company and the owner of Fortetropin ® , a proprietary bioactive composition that helps build lean muscle, announced today its results fo

Chronic pain has significant impacts on a person’s physical and mental health, often preventing people from enjoying everyday activities.

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the publication of new research demonstrating that the immunodominant SARS-CoV-2 receptor binding motif (RBM) is the least conserved region in the SARS-CoV-2 spike protein, allowing for the occurrence of mutations without disrupting human ACE2 (hACE2) binding, which mediates viral entry. Researchers also characterize the virulence and fitness of N439K,

Emisphere Technologies, Inc. (“Emisphere” or the “Company”) today announced that it has entered into a definitive agreement with Novo Nordisk A/S (“Novo Nordisk”), whereby Novo Nordisk will acquire Emisphere, on a cash-free, debt-free basis, for $1.35 billion in cash.